Fig. 1.
Change from baseline in JAK2 p.V617F allele burden at week 32 in patients randomized to ruxolitinib and to BAT. BAT best available therapy
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.